ARVN Q3 2022 Earnings — Arvinas, Inc. Revenue & Financial Results | Market Cap Arena

ARVNArvinas, Inc.

$907M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$33M+257.0% YoY

Gross Profit

$31M93.7% margin

Operating Income

-$64M-193.7% margin

Net Income

-$66M-199.4% margin

EPS (Diluted)

$-1.24

QoQ Revenue Growth

-1.8%

Cash Flow

Operating Cash Flow

-$67M

Free Cash Flow

-$69M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$713M

Stockholders' Equity

$622M

Cash & Equivalents

$133M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$9M	+257.0%
Gross Profit	$31M	$9M	+234.4%
Operating Income	-$64M	-$47M	-35.9%
Net Income	-$66M	-$47M	-41.5%